Anesthesiology and Pain Medicine

Published by: Kowsar

The Role of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the Treatment of Patients With Hepatic Disease: A Review Article

Maryam Soleimanpour 1 , Farnad Imani 2 , Saeid Safari 2 , Sarvin Sanaie 3 , Hassan Soleimanpour 1 , Hoorolnesa Ameli 4 and Seyed Moayed Alavian 5 , 6 , *
Authors Information
1 Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 Pain Research Center, Iran University of Medical Sciences, Tehran, Iran
3 Tuberculosis and Lung Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4 Students’ Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
5 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran
6 Tehran Hepatitis Center, Tehran, Iran
Article information
  • Anesthesiology and Pain Medicine: August 01, 2016, 6 (4); e37822
  • Published Online: August 10, 2016
  • Article Type: Review Article
  • Received: March 14, 2016
  • Revised: June 11, 2016
  • Accepted: June 27, 2016
  • DOI: 10.5812/aapm.37822

To Cite: Soleimanpour M, Imani F, Safari S, Sanaie S, Soleimanpour H, et al. The Role of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the Treatment of Patients With Hepatic Disease: A Review Article, Anesth Pain Med. 2016 ; 6(4):e37822. doi: 10.5812/aapm.37822.

Abstract
Copyright © 2016, Iranian Society of Regional Anesthesia and Pain Medicine (ISRAPM). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Kamath PS, Kim WR, Advanced Liver Disease Study G. The model for end-stage liver disease (MELD). Hepatology. 2007; 45(3): 797-805[DOI][PubMed]
  • 2. Murray JF, Dawson AM, Sherlock S. Circulatory changes in chronic liver disease. Am J Med. 1958; 24(3): 358-67[PubMed]
  • 3. Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. Principles of Internal Medicine. 2012;
  • 4. Parker BM, Bhatia S, Younossi Z, Henderson JM, Tetzlaff JE. Autonomic dysfunction in end-stage liver disease manifested as defecation syncope: impact of orthotopic liver transplantation. Liver Transpl Surg. 1999; 5(6): 497-501[PubMed]
  • 5. De Wolf AM. 6/2/06 Perioperative assessment of the cardiovascular system in ESLD and transplantation. Int Anesthesiol Clin. 2006; 44(4): 59-78[DOI][PubMed]
  • 6. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011; 365(2): 147-56[DOI][PubMed]
  • 7. Njoku DB. Drug-induced hepatotoxicity: metabolic, genetic and immunological basis. Int J Mol Sci. 2014; 15(4): 6990-7003[DOI][PubMed]
  • 8. Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharmacol Ther. 2013; 37(12): 1132-56[DOI][PubMed]
  • 9. Suchy FJ, Sokol RJ, Balistreri WF. Liver disease in children. 2001;
  • 10. Perrott DA, Piira T, Goodenough B, Champion GD. Efficacy and safety of acetaminophen vs ibuprofen for treating children's pain or fever: a meta-analysis. Arch Pediatr Adolesc Med. 2004; 158(6): 521-6[DOI][PubMed]
  • 11. Bosilkovska M, Walder B, Besson M, Daali Y, Desmeules J. Analgesics in patients with hepatic impairment: pharmacology and clinical implications. Drugs. 2012; 72(12): 1645-69[DOI][PubMed]
  • 12. Khalid SK, Lane J, Navarro V, Garcia-Tsao G. Use of over-the-counter analgesics is not associated with acute decompensation in patients with cirrhosis. Clin Gastroenterol Hepatol. 2009; 7(9): 994-9[DOI][PubMed]
  • 13. Fenkel JM, Coron RN, Daskalakis C, Vega M, Rossi S, Herrine SK, et al. Over-the-counter analgesics in cirrhotic patients: a case-control study examining the risk of hospitalization for liver-associated events. Scand J Gastroenterol. 2010; 45(9): 1101-9[DOI][PubMed]
  • 14. Perez-Gutthann S, Garcia-Rodriguez LA, Duque-Oliart A, Varas-Lorenzo C. Low-dose diclofenac, naproxen, and ibuprofen cohort study. Pharmacotherapy. 1999; 19(7): 854-9[PubMed]
  • 15. Sneader W. Drug Discovery: A History. 2005; [DOI]
  • 16. Bellis M. History of aspirin. 2010;
  • 17. Katzung BG, Masters SB, Trevor AJ. Basic and clinical pharmacology. 2012;
  • 18. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971; 231(25): 232-5[PubMed]
  • 19. Tohgi H, Konno S, Tamura K, Kimura B, Kawano K. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke. 1992; 23(10): 1400-3[PubMed]
  • 20. O'Connor N, Dargan PI, Jones AL. Hepatocellular damage from non-steroidal anti-inflammatory drugs. QJM. 2003; 96(11): 787-91[PubMed]
  • 21. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014; 89(1): 95-106[DOI][PubMed]
  • 22. Gines P, Arrovo V, Rodes J. Pharmacotherapy of ascites associated with cirrhosis. Drugs. 1992; 43(3): 316-32[PubMed]
  • 23. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002; 36(2): 451-5[DOI][PubMed]
  • 24. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013; 144(7): 1419-25[DOI][PubMed]
  • 25. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005; 129(2): 512-21[DOI][PubMed]
  • 26. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol. 2010; 16(45): 5651-61[PubMed]
  • 27. Imani F, Motavaf M, Safari S, Alavian SM. The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations. Hepat Mon. 2014; 14(10): 23539[DOI][PubMed]
  • 28. Bjornsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther. 2010; 32(1): 3-13[DOI][PubMed]
  • 29. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf. 2007; 6(6): 673-84[DOI][PubMed]
  • 30. Soleimanpour H, Safari S, Rahmani F, Ameli H, Alavian SM. The role of inhalational anesthetic drugs in patients with hepatic dysfunction: a review article. Anesth Pain Med. 2015; 5(1): 23409[DOI][PubMed]
  • 31. Soleimanpour H, Safari S, Rahmani F, Jafari Rouhi A, Alavian SM. Intravenous hypnotic regimens in patients with liver disease; a review article. Anesth Pain Med. 2015; 5(1): 23923[DOI][PubMed]
  • 32. Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf. 2006; 15(4): 213-20[DOI][PubMed]
  • 33. Garcia Rodriguez LA, Williams R, Derby LE, Dean AD, Jick H. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med. 1994; 154(3): 311-6[PubMed]
  • 34. Manoukian AV, Carson JL. Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention. Drug Saf. 1996; 15(1): 64-71[PubMed]
  • 35. Walker AM. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1997; 40(2): 201-8[PubMed]
  • 36. Lewis HJ, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty J, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983; 309(7): 396-403[DOI][PubMed]
  • 37. Julian DG, Chamberlain DA, Pocock SJ. A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. BMJ. 1996; 313(7070): 1429-31[PubMed]
  • 38. Levy G, Tsuchiya T. Salicylate accumulation kinetics in man. N Engl J Med. 1972; 287(9): 430-2[DOI][PubMed]
  • 39. Gaudreault P, Temple AR, Lovejoy FH. The relative severity of acute versus chronic salicylate poisoning in children: a clinical comparison. Pediatrics. 1982; 70(4): 566-9[PubMed]
  • 40. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998; 280(22): 1930-5[PubMed]
  • 41. The Progeria Handbook. 2010;
  • 42. Hurwitz ES. Reye's syndrome. Epidemiol Rev. 1989; 11: 249-53[PubMed]
  • 43. Gosalakkal JA, Kamoji V. Reye syndrome and reye-like syndrome. Pediatr Neurol. 2008; 39(3): 198-200[DOI][PubMed]
  • 44. Bushra R, Aslam N. An overview of clinical pharmacology of Ibuprofen. Oman Med J. 2010; 25(3): 155-1661[DOI][PubMed]
  • 45. Casper D, Yaparpalvi U, Rempel N, Werner P. Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett. 2000; 289(3): 201-4[PubMed]
  • 46. Durkin E, Moran AP, Hanson PJ. Apoptosis induction in gastric mucous cells in vitro: lesser potency of Helicobacter pylori than Escherichia coli lipopolysaccharide, but positive interaction with ibuprofen. J Endotoxin Res. 2006; 12(1): 47-56[DOI][PubMed]
  • 47. Ayres JG, Fleming DM, Whittington RM. Asthma death due to ibuprofen. Lancet. 1987; 1(8541): 1082[PubMed]
  • 48. Gaziano JM, Gibson CM. Potential for drug-drug interactions in patients taking analgesics for mild-to-moderate pain and low-dose aspirin for cardioprotection. Am J Cardiol. 2006; 97(9A): 23-9[DOI][PubMed]
  • 49. Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol. 2008; 101(7): 1060-3[DOI][PubMed]
  • 50. Dooley JM, Gordon KE, Wood EP, Brna PM, MacSween J, Fraser A. Caffeine as an adjuvant to ibuprofen in treating childhood headaches. Pediatr Neurol. 2007; 37(1): 42-6[DOI][PubMed]
  • 51. Pargal A, Kelkar MG, Nayak PJ. The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. Biopharm Drug Dispos. 1996; 17(6): 511-9[DOI][PubMed]
  • 52. Naidoo V, Swan GE. Diclofenac toxicity in Gyps vulture is associated with decreased uric acid excretion and not renal portal vasoconstriction. Comp Biochem Physiol C Toxicol Pharmacol. 2009; 149(3): 269-74[DOI][PubMed]
  • 53. Solomon DH, Avorn J, Sturmer T, Glynn RJ, Mogun H, Schneeweiss S. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. 2006; 54(5): 1378-89[DOI][PubMed]
  • 54. Swan G, Naidoo V, Cuthbert R, Green RE, Pain DJ, Swarup D, et al. Removing the threat of diclofenac to critically endangered Asian vultures. PLoS Biol. 2006; 4(3): 66[DOI][PubMed]
  • 55. Sehgal N, Colson J, Smith HS. Chronic pain treatment with opioid analgesics: benefits versus harms of long-term therapy. Expert Rev Neurother. 2013; 13(11): 1201-20[DOI][PubMed]
  • 56. Giles W, Bisits A. Preterm labour. The present and future of tocolysis. Best Pract Res Clin Obstet Gynaecol. 2007; 21(5): 857-68[DOI][PubMed]
  • 57. Akbarpour F, Afrasiabi A, Vaziri ND. Severe hyperkalemia caused by indomethacin and potassium supplementation. South Med J. 1985; 78(6): 756-7[PubMed]
  • 58. British National Formulary. 2013; : 665
  • 59. Weintraub M, Jacox RF, Angevine CD, Atwater EC. Piroxicam (CP 16171) in rheumatoid arthritis: a controlled clinical trial with novel assessment techniques. J Rheumatol. 1977; 4(4): 393-404[PubMed]
  • 60. Pringsheim T, Davenport WJ, Dodick D. Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology. 2008; 70(17): 1555-63[DOI][PubMed]
  • 61. Trinus FP, Mokhort NA, Yagupol'skii LM, Fadeicheva AG, Danilenko VS, Ryabukha TK, et al. Mefenamic acid ? A nonsteroid antiinflammatory agent. Pharm Chemistry J. 1977; 11(12): 1706-11[DOI]
  • 62. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997; 40(9): 1347-65[DOI][PubMed]
  • 63. McCormack PL. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs. 2011; 71(18): 2457-89[DOI][PubMed]
  • 64. Derry S, Moore RA. Single dose oral celecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2013; (10)[DOI][PubMed]
  • 65. Mathew ST, Devi SG, Prasanth VV, Vinod B. Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review. ISRN Pharmacol. 2011; 2011: 480291[DOI][PubMed]
  • 66. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001; 286(8): 954-9[PubMed]
  • 67. Bateman DN. NSAIDs: time to re-evaluate gut toxicity. Lancet. 1994; 343(8905): 1051-2[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments